CIITA antibody (C-Term)

Catalog No. ABIN927649

This Rabbit Polyclonal antibody specifically detects CIITA in WB. It exhibits reactivity toward Mouse, Rat and Dog.

Quick Overview for CIITA antibody (C-Term) (ABIN927649)

Target: CIITA (Class II, Major Histocompatibility Complex, Transactivator (CIITA))

Reactivity: Mouse, Rat, Dog

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CIITA antibody is un-conjugated

Application: Western Blotting (WB)

Product Details anti-CIITA Antibody

Binding Specificity: C-Term

Cross-Reactivity: Rat (Rattus), Dog (Canine)

Purification: Purified

Immunogen: C2 TA antibody was raised in rabbit using the C terminal of C2 A as the immunogen

Application Details

Application Notes: WB: 0.125 µg/mL
Optimal conditions should be determined by the investigator.

Comment:

C2TA Blocking Peptide, (ABIN5612508), is also available for use as a blocking control in assays to test for specificity of this C2TA antibody

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: Lot specific

Buffer: Lyophilized powder. Add 50 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: 4 °C/-20 °C

Storage Comment: Store at 4 °C, following reconstitution, aliquot and store at -20 °C.

Target Details for CIITA

Target: CIITA (Class II, Major Histocompatibility Complex, Transactivator (CIITA))

Alternative Name: C2TA

Background: C2ta is essential for transcriptional activity of the HLA class II promoter, activation is via the proximal promoter. No DNA binding of in vitro translated CIITA was detected. C2ta may act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both. Alternatively it may activate HLA class II transcription by modifying proteins that bind to the MHC class II promoter. Synonyms: Polyclonal C2TA antibody, Anti-C2TA antibody.

Pathways: Cancer Immune Checkpoints